In the September 2017 issue, in the article “CRISPR patent estate splinters” initially published, the first two sentences of paragraph 2, on p. 809, column 2, incorrectly stated that MilliporeSigma had received patent grants for the proxy-CRISPR technology, whereas it has filed patent applications for this technology. The sentences, which follow, have been replaced: “It was a 'dead' version of Cas9 that secured patent rights for the life sciences arm of Merck KGA. The Darmstadt, Germany -based pharma's wholly owned subsidiary MilliporeSigma, received both European and Australian patents for its 'proxy-CRISPR' version of the genome editing system.” The business has received an Australian patent grant and a notice of intention from the European Patent Office for a patent that covers the integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR. In two instances in the same paragraph a “Merck” spokesperson should have been identified as being from “MilliporeSigma” and, similarly, “Merck claims” should have been “MilliporeSigma” claims. In addition, KGaA was misspelled as KGA; the third mention of “Neuman” was misspelled as “Newman.” The errors were corrected in the HTML and PDF versions of the article.

In the September 2017 issue, In the article “What's app? Helix wants you to quiz you genome--some of it for fun” initially published, a disease-carrier screening app was described as “Sema4, provided by Eric Schadt's group at Mt. Sinai Hospital...” The app is called “CarrierCheck” and was developed by Sema4, a company spun out of Mt. Sinai and led by Eric Schadt. The errors were corrected in the HTML and PDF versions of the article.